A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes

被引：64

作者：

Chevillotte, Meike ^{[2
]}

von Einem, Jens ^{[2
]}

Meier, Benjamin M. ^{[1
]}

Lin, Feng-Mao ^{[3
]}

Kestler, Hans A. ^{[1
]}

Mertens, Thomas ^{[2
]}

机构：

[1] Univ Ulm, Inst Neural Informat Proc, D-89069 Ulm, Germany

[2] Univ Hosp Ulm, Inst Virol, D-89081 Ulm, Germany

[3] Natl Chiao Tung Univ, Inst Bioinformat & Syst Biol, Hsinchu 300, Taiwan

来源：

ANTIVIRAL RESEARCH | 2010年 / 85卷 / 02期

关键词：

UL97; UL54; Genotype; Clinical outcome; HCMV; GCV; CDV; FOS; STEM-CELL TRANSPLANTATION; DNA-POLYMERASE MUTATIONS; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; GANCICLOVIR RESISTANCE; IMMUNOCOMPROMISED PATIENTS; MULTIDRUG-RESISTANCE; FOSCARNET RESISTANCE; CMV INFECTION; IN-VITRO; RENAL-TRANSPLANTATION;

D O I：

10.1016/j.antiviral.2009.10.004

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Drug resistant strains of human cytomegalovirus (HCMV) in patients at risk may increasingly develop into a problem in the clinical setting. Genotypic resistance testing is becoming the method of choice, but requires previous phenotypic characterisation of each newly found mutation. In order to facilitate the interpretation of the patient's CMV sequence data, a web-based search tool was generated that links the sequence to a database containing all published UL97 (protein kinase) and UL54 (DNA polymerase) mutations and corresponding antiviral drug susceptibility phenotypes. It is reasonable to assume that HCMV drug resistance testing will provide relevant data for an adjustment of therapy and on prognosis of clinical outcome. HCMV drug susceptibility testing will become even more important once new drugs will be available for therapy allowing a wider choice of antiviral agents to treat HCMV disease. These topics will also play a pivotal role for optimising antiviral therapy of HCMV- and other viral diseases. (C) 2009 Elsevier B.V. All rights reserved.

引用

页码：318 / 327

页数：10

共 94 条

[1] Gapped BLAST and PSI-BLAST: a new generation of protein database search programs [J].

Altschul, SF ;

Madden, TL ;

Schaffer, AA ;

Zhang, JH ;

Zhang, Z ;

Miller, W ;

Lipman, DJ .

NUCLEIC ACIDS RESEARCH, 1997, 25 (17) :3389-3402

[2] BASIC LOCAL ALIGNMENT SEARCH TOOL [J].

ALTSCHUL, SF ;

GISH, W ;

MILLER, W ;

MYERS, EW ;

LIPMAN, DJ .

JOURNAL OF MOLECULAR BIOLOGY, 1990, 215 (03) :403-410

[3]

ANDREI G, 2009, DRUG TARGETS, V9, P201

[4]

Andrei G, 2008, CURR OPIN INVEST DR, V9, P132

[5] Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS [J].

Baldanti, F ;

Underwood, MR ;

Stanat, SC ;

Biron, KK ;

Chou, SW ;

Sarasini, A ;

Silini, E ;

Gerna, G .

JOURNAL OF VIROLOGY, 1996, 70 (03) :1390-1395

[6] Emergence of multiple drug-resistant human cytomegalovirus variants in 2 patients with human immunodeficiency virus infection unresponsive to highly active antiretroviral therapy [J].

Baldanti, F ;

Paolucci, S ;

Parisi, A ;

Meroni, L ;

Gerna, G .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (08) :1146-1149

[7] Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system [J].

Baldanti, F ;

Michel, D ;

Simoncini, L ;

Heuschmid, M ;

Zimmermann, A ;

Minisini, R ;

Schaarschmidt, P ;

Schmid, T ;

Gerna, G ;

Mertens, T .

ANTIVIRAL RESEARCH, 2002, 54 (01) :59-67

[8] A HUMAN CYTOMEGALOVIRUS MUTANT RESISTANT TO THE NUCLEOSIDE ANALOG 9-([2-HYDROXY-1-(HYDROXYMETHYL)ETHOXY]METHYL)GUANINE (BW B759U) INDUCES REDUCED LEVELS OF BW B759U TRIPHOSPHATE [J].

BIRON, KK ;

FYFE, JA ;

STANAT, SC ;

LESLIE, LK ;

SORRELL, JB ;

LAMBE, CU ;

COEN, DM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (22) :8769-8773

[9] Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action [J].

Biron, KK ;

Harvey, RJ ;

Chamberlain, SC ;

Good, SS ;

Smith, AA ;

Davis, MG ;

Talarico, CL ;

Miller, WH ;

Ferris, R ;

Dornsife, RE ;

Stanat, SC ;

Drach, JC ;

Townsend, LB ;

Koszalka, GW .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2365-2372

[10] Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation [J].

Boeckh, M ;

Fries, B ;

Nichols, WG .

PEDIATRIC TRANSPLANTATION, 2004, 8 :19-27

← 1 2 3 4 5 6 7 8 9 10 →